U.S. markets close in 3 hours 49 minutes
  • S&P 500

    4,581.96
    +43.53 (+0.96%)
     
  • Dow 30

    35,212.74
    +632.66 (+1.83%)
     
  • Nasdaq

    15,115.98
    +30.50 (+0.20%)
     
  • Russell 2000

    2,186.93
    +27.62 (+1.28%)
     
  • Crude Oil

    68.25
    +1.99 (+3.00%)
     
  • Gold

    1,785.40
    +1.50 (+0.08%)
     
  • Silver

    22.34
    -0.14 (-0.60%)
     
  • EUR/USD

    1.1284
    -0.0033 (-0.29%)
     
  • 10-Yr Bond

    1.3940
    +0.0510 (+3.80%)
     
  • GBP/USD

    1.3253
    +0.0018 (+0.13%)
     
  • USD/JPY

    113.3500
    +0.5500 (+0.49%)
     
  • BTC-USD

    49,116.24
    +613.84 (+1.27%)
     
  • CMC Crypto 200

    1,265.70
    +5.54 (+0.44%)
     
  • FTSE 100

    7,232.28
    +109.96 (+1.54%)
     
  • Nikkei 225

    27,927.37
    -102.20 (-0.36%)
     

China Biologic receives $4.59 bln take-private buyout offer

Sept 18 (Reuters) - China Biologic Products Holdings Inc said on Wednesday it had received a take-private deal for $4.59 billion in cash from a consortium of buyers.

Shares of the company, which develops plasma-based therapies and was listed on the Nasdaq in 2009, were up 7% after market.

The offer of $120 per share represents a premium of 16.3% to China Biologic's Wednesday close of $103.10.

The buyer group includes Beachhead Holdings Ltd, CITIC Capital China Partners IV LP, PW Medtech Group Ltd, Parfield International Ltd, HH Sum-XXII Holdings Ltd and V-Sciences Investments Pte Ltd. (https://reut.rs/2mnFvlQ)

In August 2018, China Biologic rejected a $3.9 billion offer from a consortium led by its former chief executive officer. (https://reut.rs/2BKMZXo) (Reporting by Bharath Manjesh in Bengaluru; Editing by Shounak Dasgupta)